Veradermics, Inc (MANE) Stock Price & Analysis
Veradermics, Inc (MANE) rose 0.78% to USD 98.51 as of September 8, 2026 at 09:36 UTC, according to Nexqual real-time market data.
MANE last closed at USD 98.51; the session ranged USD 97.2–99.84 on volume of 362,791 shares. Market capitalization is —, with a 52-week range of USD 32–131.24 (NYQ). Source: Nexqual, September 8, 2026 at 09:36 UTC.
Key Statistics (as of September 8, 2026 at 09:36 UTC)
| Price | USD 98.51 |
|---|---|
| Change | ▲ 0.78% (up) |
| Previous Close | USD 98.51 |
| Open | USD 98.51 |
| Day Range | USD 97.2 – 99.84 |
| 52-Week Range | USD 32 – 131.24 |
| Volume | 362,791 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (MANE)
Nexqual's technical model rates MANE "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.62 (neutral) |
| vs SMA50 | Below (USD 110.29) |
| MACD | -3.17 (negative) |
From Veradermics, Inc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary research indicates that 93% of patients would like to address their PHL yet only 9% are satisfied with their current treatment.
- In our proprietary market surveys of Americans with PHL, survey respondents cited more rapid onset of growth as a primary desire in a treatment for PHL.
- Our proprietary market research identified that the second most common reason that current OTC users are not using a prescription product is lack of awareness of prescription offerings.
Partnerships
- If VDPHL01 is approved as the first oral therapy for women, we believe it could be especially well-received among the approximately 30 million female PHL patients in the United States. 8 n Evaluate strategic collaboration to maximize the value of our product candidates and deliver meaningful benefits to patients.
- We may selectively consider strategic collaboration opportunities to expand the reach and maximize the value of VDPHL01. n Identify additional solutions to pervasive unmet needs in dermatology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 92.51 | ▲ 0.96% |
| SYRE | Spyre Therapeutics, Inc. | USD 88.98 | ▲ 2.22% |
| COAG | Hemab Therapeutics Holdings, In | USD 44.41 | ▼ 0.65% |
| KLRA | Kailera Therapeutics, Inc. | USD 16.23 | ▲ 2.4% |
| ABSI | Absci Corporation | USD 8.82 | ▲ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:36 UTC. This page is informational and not investment advice.